Cipla launches India's first sputum inflammometry lab in Mumbai
The facility sets a new benchmark in respiratory diagnostics
The facility sets a new benchmark in respiratory diagnostics
DCGI-approved semaglutide syringes for diabetes and obesity expand treatment choices and improve affordability
The hospital successfully treats two complex high-risk cardiac patients using advanced minimally invasive heart surgeries
The approval is expected to support the company’s presence in regulated international markets and further strengthen its position as a reliable pharma manufacturing partner
The filing is backed by Phase III data from the lidERA Breast Cancer study
Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) single-dose vials is the bioequivalent to the reference listed drug (RLD) Halaven injection of Eisai, Inc.
The transaction includes an upfront payment of $1.55 billion, along with up to $1.1 billion in regulatory and commercial milestone payments
First-in-class treatment of life-threatening, drug-resistant Acinetobacter baumannii infections advancing toward Phase II clinical proof-of-concept
This facility plays an important role in Granules’ global manufacturing and supply network
Subscribe To Our Newsletter & Stay Updated